.jpg?format=webp&quality=80&width=3840)
A study conducted in the United Kingdom between 1999 and 2009 involving 82,429 men between 50 and 69 years of age who received a prostate-specific antigen (PSA) test found that after 15 years of follow-up, prostate cancer-specific mortality was low regardless of the treatment assigned. The study compared the effectiveness of active monitoring, prostatectomy, and radiotherapy for treating localized prostate cancer. No differential effects on cancer-specific mortality were noted in relation to the baseline PSA level, tumor stage or grade, or risk-stratification score. The study concludes that the choice of therapy involves weighing trade-offs between benefits and harms associated with treatments for localized prostate cancer.
Like
Save
Share